Status:
UNKNOWN
To Explore the Effect of GH Pretreatment on Clinical Outcomes in Patients With Low Ovarian Reserve
Lead Sponsor:
Guangzhou First People's Hospital
Conditions:
GH
Low Ovarian Reserve
Eligibility:
FEMALE
Brief Summary
Growth hormone (GH) has been used in the field of assisted reproduction technology for over 30 years. Studies for GH have been exploring in the applicable population, drug dosage, starting time and ti...
Eligibility Criteria
Inclusion
- low ovarian reserve(AMH \<1.2ng/ml, or AFC \<5);
- patients who have not participated in any clinical trials within the three months;
- patients who voluntarily signed informed consent.
Exclusion
- patients with BMI ≥30kg/m2;
- patients with medical diseases such as endocrine and metabolic diseases, autoimmune disease, etc;
- ovarian neoplasm that ≥4 cm in diameter and has no clear pathological diagnosis by surgery;
- complicated with adenomyosis, endometriosis confirmed by surgery;
- patients with untreated abnormal intrauterine environment, such as uterine effusion, endometritis, etc;
- untreated hydrosalpinx.
Key Trial Info
Start Date :
May 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04384783
Start Date
May 26 2020
End Date
April 30 2022
Last Update
May 21 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.